Roivant Sciences (NASDAQ:ROIV) Earns Buy Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Roivant Sciences (NASDAQ:ROIV) in a research note issued to investors on Monday morning, Benzinga reports. They currently have a $18.00 target price on the stock.

Several other research firms have also commented on ROIV. Cantor Fitzgerald reissued an overweight rating on shares of Roivant Sciences in a research report on Tuesday, June 18th. Piper Sandler increased their price target on shares of Roivant Sciences from $20.00 to $22.00 and gave the company an overweight rating in a research report on Wednesday, July 10th. One research analyst has rated the stock with a hold rating and nine have issued a buy rating to the stock. According to MarketBeat.com, Roivant Sciences has an average rating of Moderate Buy and a consensus target price of $17.10.

Roivant Sciences Stock Up 2.7 %

Shares of ROIV opened at $11.79 on Monday. The firm has a market capitalization of $8.71 billion, a P/E ratio of 2.33 and a beta of 1.24. Roivant Sciences has a 12-month low of $8.24 and a 12-month high of $13.24. The company has a current ratio of 25.24, a quick ratio of 25.24 and a debt-to-equity ratio of 0.07. The firm has a fifty day moving average price of $10.91 and a 200-day moving average price of $10.93.

Roivant Sciences (NASDAQ:ROIV) last released its quarterly earnings data on Thursday, August 8th. The company reported $0.12 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.33. The company had revenue of $55.10 million during the quarter, compared to analyst estimates of $30.72 million. Roivant Sciences had a net margin of 3,484.86% and a negative return on equity of 25.05%. The firm’s revenue for the quarter was up 155.1% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.38) earnings per share. Equities research analysts expect that Roivant Sciences will post -1.12 earnings per share for the current year.

Institutional Investors Weigh In On Roivant Sciences

Hedge funds and other institutional investors have recently made changes to their positions in the company. Mutual of America Capital Management LLC lifted its position in shares of Roivant Sciences by 0.4% during the 2nd quarter. Mutual of America Capital Management LLC now owns 327,079 shares of the company’s stock valued at $3,457,000 after buying an additional 1,142 shares in the last quarter. Acadian Asset Management LLC lifted its holdings in Roivant Sciences by 23.2% in the 2nd quarter. Acadian Asset Management LLC now owns 8,510 shares of the company’s stock valued at $89,000 after purchasing an additional 1,603 shares in the last quarter. Allspring Global Investments Holdings LLC lifted its holdings in Roivant Sciences by 42.6% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 5,385 shares of the company’s stock valued at $60,000 after purchasing an additional 1,608 shares in the last quarter. nVerses Capital LLC purchased a new position in Roivant Sciences in the 2nd quarter valued at $34,000. Finally, Headlands Technologies LLC acquired a new stake in shares of Roivant Sciences in the 4th quarter worth $36,000. Institutional investors and hedge funds own 64.76% of the company’s stock.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.